GINGIVAL NEUROFIBROMA IN NON SYNDROMIC NEUROFIBROMATOSIS TYPE 1
1 Homeira Saebnoori, 2 Asoma Awudu
1 Assistant professor, Department of Oral & Maxillofacial Pathology,
School of Dentistry, Tehran University of Medical Sciences, Iran
2 General Dentist, Dental Department, Tamale Teaching Hospital, Tamale,
Ghana
CONSENT STATEMENT
Written informed consent was obtained from the patient to publish this
report in accordance with the journal’s patient consent policy.
INTRODUCTION
Neurofibromatosis type 1 also known as von Recklinghausen’s disease is a
relatively common disease of nervous tissues. It is an autosomal
dominant disease caused by a mutation in the NF1 gene characteristically
shown as multiple neurofibromas and cafe ´-au-lait spots (1). Per the
nature of NF1 gene mutation, NF1 has multiple and varied clinical
manifestations, from mild to extreme forms that cause impairment and
disability (2)
In 72% of patients with NF1 oral manifestations occur (3) but rarely
occur as gingival enlargement. In this paper, we report a rare
manifestation of NF1 in the lingual gingiva in a patient without a
family history of neurofibromatosis.
CASE PRESENTATION
An 18-year-old male was referred to the Department of Oral Medicine,
Shahid Beheshti University of Medical Sciences (Iran, Tehran) for
evaluation of painless swelling of the left posterior lingual vestibule
of the mandible and tooth mobility in that region for two weeks. The
patient had no history of previous trauma or medical problems. Intraoral
examination showed a firm swelling extending from teeth no 33 to 35 with
intact mucosa (Figure 1). The local teeth were vital. The patient’s oral
hygiene was good. Imaging, in the panoramic radiograph, showed nothing
notable. It appeared that the infra alveolar canal was intact. Due to
clinical, and histopathologic features, “Neurofibroma” was considered.
On gross examination, the lesion consists of one piece of nodular oval
cream-white tissue with firm consistency covered by irregular mucosa
measuring 1.3×1.1×0.4 cm.
Histopathologic sections revealed a mesenchymal tumor composed of
fibrous to myxoid connective tissue with abundant spindle cells with
wavy nuclei, few mast cells, giant fibroblasts, and scattered chronic
inflammatory cells. The lesion is covered by para-keratinized stratified
squamous epithelium (Figure 2). The nature of spindle cells was
determined through immunohistochemistry (IHC) which were scattered
positive for S-100 protein (Figure 3). But IHC staining was negative for
Desmin, SMA (Smooth muscle Actin), and Myogenin. According to the
aforementioned histopathologic, IHC features, more evaluation clinically
and family history have been done. The patient stated that he had no
family history of such lesions. Then we observed his body for other
clinical features to confirm “Neurofibromatosis” and we found more
café-au-lait macules on the trunk, neck, and scalp, axillary freckling,
and Lisch nodules in his eyes (Figure 4). He mentioned that he had a
history of macular lesions of scalp biopsy and a histopathological
report of “Nevus Spilus”. Because it appears that NF shows
nonaggressive behavior, no additional treatment was done just following
him for recurrent or malignancy. The recurrent lesion was undergone
surgical treatment the next year after the first biopsy. There was no
recurrence during a 24-month follow-up period. Informed consent was
obtained from the patient for publishing her clinical photography.
DISCUSSION
The two main forms of neurofibromatosis are type 1 (NF1) and type 2
(NF2) of which the former is characterized by café-au-lait spots and
neurofibroma and the latter by bilateral acoustic neuroma. The more
common of the two, NF1, was first described in 1882 by Friedrich Daniel
von Recklinghausen and it is caused by the mutation of genes located on
chromosome 17 (17q11.2) (4). NF1 gene produces neurofibromin, a tumor
suppressor protein whose signaling inhibits the ras signal
transduction pathway and so controls cell growth (5).
The etiology of neurofibromatosis, an autosomal dominant neurocutaneous
syndrome, is unknown although several theories have been proposed.
Approximately 50% of the cases of NF1 are sporadic and represent a
spontaneous mutation. Sporadic NF1 is considered one of the diseases
with the highest spontaneous mutations affecting humankind (6).NF1
impacts cognitive development in affected children. Patients with
sporadic NF1 have significantly better IQ than those with familial NF1.
This has an impact on the long-term care and management of patients with
NF1 (7).
Oral manifestations of NF1 are seen in approximately 72% of NF1 cases
(8) and may present as impacted, displaced, supernumerary, or missing
teeth (9). Gingival manifestations of neurofibroma are rare and
constitute only 2% of the cases that appear in the oral cavity (9). The
present case showed a firm swelling extending from the lingual side of
the mandibular left canine to the first premolar on the same side. The
lesion had intact covering mucosa and an intact mandibular canal on the
panoramic radiograph. Teeth in the lesion environment were vital and had
healthy periodontium. Gingival neurofibroma may lead to periodontal
problems when it obstructs routine oral hygiene care.
The most common mode of treatment for oral neurofibroma is surgical
excision (10). For plexiform neurofibroma, which possesses a high risk
of malignant transformation, oral selective mitogen-activated protein
kinase inhibitor Selumetinib has now become the standard of care,
especially in children where lesion shrinkage is 68% (11).
Patients with NF1 have a higher lifetime risk of malignant
transformation than the general population which is estimated at about
5% for localized neurofibroma (10) and as high as 29% for plexiform
neurofibroma (12).
CONCLUSION
It is prudent that dental professionals are aware of the oral
manifestations of NF1 for timely detection of the condition, and for
appropriate preventive follow-up for early diagnosis of any eventual
malignant transformation. Gingival manifestations of neurofibroma may
cause periodontal problems so early management is key, especially in the
patient with no familial history.
DECLARATION OF CONFLICT OF INTEREST
The authors report no conflict of interest.
REFERENCES
- Thomson SA, Fishbein L, Wallace MR. NF1 mutations and molecular
testing. Journal of child neurology. 2002 Aug;17(8):555-61.
- HE P, WF J. Multiple neurofibromatosis with oral lesions; review of
the literature and report of a case. Oral Surgery, Oral Medicine, and
Oral Pathology. 1955 Mar 1;8(3):263-80.
- Shapiro SD, Abramovitch K, Van Dis ML, Skoczylas LJ, Langlais RP,
Jorgenson RJ, Young RS, Riccardi VM. Neurofibro matosis: oral and
radiographic manifestations. Oral Surgery, Oral Medicine, Oral
Pathology. 1984 Oct 1;58(4):493-8.
- Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM,
Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH. Type
1 neurofibromatosis gene: identification of a large transcript
disrupted in three NF1 patients. Science. 1990 Jul 13;249(4965):181-6.
- Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1:
modeling CNS dysfunction. Journal of Neuroscience. 2012 Oct
10;32(41):14087-93.
- D’Ambrosio JA, Langlais RP, Young RS. Jaw and skull changes in
neurofibromatosis. Oral surgery, oral medicine, oral pathology. 1988
Sep 1;66(3):391-6.
- Freedus MS, Doyle PK. Multiple neurofibromatosis with oral
manifestations. Journal of Oral Surgery (American Dental Association:
1965). 1975 May 1;33(5):360-3.
- Geist JR, Gander DL, Stefanac SJ. Oral manifestations of
neurofibromatosis types I and II. Oral surgery, oral medicine, oral
pathology. 1992 Mar 1;73(3):376-82.
- Friedrich, R.E.; Giese, M.; Schmelzle, R.; Mautner, V.F.; Scheuer,
H.A. Jaw malformations plus displacement and numerical aberrations of
teeth in neurofibromatosis type 1: A descriptive analysis of 48
patients based on panoramic radiographs and oral findings. J.
Craniomaxillofac. Surg. 2003, 31, 1–9. [CrossRef]
- García de Marcos JA, Dean Ferrer A, Alamillos Granados F, Ruiz Masera
JJ, García de Marcos MJ, Vidal Jiménez A, Valenzuela Salas B, García
Lainez A. Gingival neurofibroma in a neurofibromatosis type 1 patient:
Case report. Medicina Oral, Patología Oral y Cirugía Bucal (Internet).
2007 Aug;12(4):287-91.
- Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss
B, Kim A, Bornhorst M, Shah AC, Martin S. Selumetinib in children with
inoperable plexiform neurofibromas. New England Journal of Medicine.
2020 Apr 9;382(15):1430-42.
- Visnapuu V, Peltonen S, Alivuotila L, Happonen RP, Peltonen J.
Craniofacial and oral alterations in patients with Neurofibromatosis
1. Orphanet journal of rare diseases. 2018 Dec;13:1-9.